|
1
|
Rickels FR, Levine M and Edwards RL:
Hemostatic alterations in cancer patients. Cancer Metastasis Rev.
11:237–248. 1992. View Article : Google Scholar
|
|
2
|
Heit JA, Silverstein MD, Mohr DN,
Petterson TM, O’Fallon WM and Melton LJ III: Risk factors for deep
vein thrombosis and pulmonary embolism: a population-based
case-control study. Arch Intern Med. 160:809–815. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kasthuri R, Taubman M and Mackman N: Role
of tissue factor in cancer. J Clin Oncol. 27:4834–4838. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amirkhosravi A, Meyer T, Amaya M, Davila
M, Mousa SA, Robson T and Francis JL: The role of tissue factor
pathway inhibitor in tumor growth and metastasis. Semin Thromb
Hemost. 33:643–652. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Y, Jiang P, Capkova K, Xue D, Ye L,
Sinha SC, Mackman N, Janda KD and Liu C: Tissue factor-activated
coagulation cascade in the tumor microenvironment is critical for
tumor progression and an effective target for therapy. Cancer Res.
71:6492–6502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hron G, Kollars M, Binder BR, Eichinger S
and Kyrle PA: Identification of patients at low risk for recurrent
venous thromboembolism by measuring thrombin generation. JAMA.
296:397–402. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zigler M, Kamiya T, Brantley EC, Villares
GJ and Bar-Eli M: PAR-1 and thrombin: the ties that bind the
microenvironment to melanoma metastasis. Cancer Res. 71:6561–6566.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wojtukiewicz MZ, Zacharski LR, Memoli VA,
Kisiel W, Kudryk BJ, Rousseau SM and Stump DC: Malignant melanoma.
Interaction with coagulation and fibrinolysis pathways in situ. Am
J Clin Pathol. 93:516–521. 1990.PubMed/NCBI
|
|
9
|
Zacharski LR, Memoli VA, Morain WD,
Schlaeppi JM and Rousseau SM: Cellular localization of
enzymatically active thrombin in intact human tissues by hirudin
binding. Thromb Haemost. 73:793–797. 1995.PubMed/NCBI
|
|
10
|
Ornstein DL and Zacharski LR: Treatment of
cancer with anticoagulants: rationale in the treatment of melanoma.
Int J Hematol. 73:157–161. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Even-Ram S, Uziely B, Cohen P,
Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I and
Bar-Shavit R: Thrombin receptor overexpression in malignant and
physiological invasion processes. Nat Med. 4:909–914. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grisaru-Granovsky S, Salah Z, Maoz M,
Pruss D, Beller U and Bar-Shavit R: Differential expression of
protease activated receptor 1 (Par1) and pY397FAK in benign and
malignant human ovarian tissue samples. Int J Cancer. 113:372–378.
2005. View Article : Google Scholar
|
|
13
|
Henrikson KP, Salazar SL, Fenton JW II and
Pentecost BT: Role of thrombin receptor in breast cancer
invasiveness. Br J Cancer. 79:401–406. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Radjabi AR, Sawada K, Jagadeeswaran S,
Eichbichler A, Kenny HA, Montag A, Bruno K and Lengyel E: Thrombin
induces tumor invasion through the induction and association of
matrix metalloproteinase-9 and beta1-integrin on the cell surface.
J Biol Chem. 283:2822–2834. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang RS, Chiang HS, Tang CH, Yeh CS and
Huang TF: Rhodostomin inhibits thrombin-enhanced adhesion of ROS
17/2.8 cells through the blockade of alphavbeta3 integrin. Toxicon.
46:387–393. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Even-Ram SC, Maoz M, Pokroy E, Reich R,
Katz BZ, Gutweini P, Altevogti P and Bar-Shavit R: Tumor cell
invasion is promoted by activation of protease activated receptor-1
in cooperation with the alpha v beta 5 integrin. J Biol Chem.
276:10952–10962. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiang HS, Yang RS and Huang TF: Thrombin
enhances the adhesion and migration of human colon adenocarcinoma
cells via increased beta 3-integrin expression on the tumor cell
surface and their inhibition by the snake venom peptide,
rhodostomin. Br J Cancer. 73:902–908. 1996. View Article : Google Scholar
|
|
18
|
Chiang HS, Yang RS and Huang TF: The
Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell
adhesion to extracellular matrices and platelet aggregation caused
by Saos-2 human osteosarcoma cells. Br J Cancer. 71:265–270. 1995.
View Article : Google Scholar
|
|
19
|
Bode W, Turk D and Karshikov A: The
refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg
chloromethylketone-inhibited human alpha-thrombin: structure
analysis, overall structure, electrostatic properties, detailed
active-site geometry, and structure-function relationships. Protein
Sci. 1:426–471. 1992. View Article : Google Scholar
|
|
20
|
Bar-Shavit R, Sabbah V, Lampugnani MG,
Marchisio PC, Fenton JW II, Vlodavsky I and Dejana E: An
Arg-Gly-Asp sequence within thrombin promotes endothelial cell
adhesion. J Cell Biol. 112:335–344. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bar-Shavit R, Eskohjido Y, Fenton JW II,
Esko JD and Vlodavsky I: Thrombin adhesive properties: induction by
plasmin and heparan sulfate. J Cell Biol. 123:1279–1287. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsopanoglou NE, Andriopoulou P and
Maragoudakis ME: On the mechanism of thrombin-induced angiogenesis:
involvement of alphavbeta3-integrin. Am J Physiol Cell Physiol.
283:C1501–C1510. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsopanoglou NE, Papaconstantinou ME,
Flordellis CS and Maragoudakis ME: On the mode of action of
thrombin-induced angiogenesis: thrombin peptide, TP508, mediates
effects in endothelial cells via alphavbeta3 integrin. Thromb
Haemost. 92:846–857. 2004.PubMed/NCBI
|
|
24
|
Sajid M, Zhao R, Pathak A, Smyth SS and
Stouffer GA: Alphavbeta3-integrin antagonists inhibit
thrombin-induced proliferation and focal adhesion formation in
smooth muscle cells. Am J Physiol Cell Physiol. 285:C1330–C1338.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Papaconstantinou ME, Carrell CJ, Pineda
AO, Bobofchak KM, Mathews FS, Flordellis CS, Maragoudakis ME,
Tsopanoglou NE and Di Cera E: Thrombin functions through its RGD
sequence in a non-canonical conformation. J Biol Chem.
280:29393–29396. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bar-Shavit R, Eldor A and Vlodavsky I:
Binding of thrombin to subendothelial extracellular matrix.
Protection and expression of functional properties. J Clin Invest.
84:1096–1104. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hernández-Rodríguez NA, Correa E, Sotelo
R, Gómez-Ruiz C, Contreras-Paredes A and Green L: Thrombin is
present in the lungs of patients with primary extremity
osteosarcoma and pulmonary metastases. Int J Biol Markers.
17:189–195. 2002.PubMed/NCBI
|
|
28
|
Fenton JW II: Regulation of thrombin
generation and functions. Semin Thromb Hemost. 14:234–240. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weitz JI, Hudoba M, Massel D, Maraganore J
and Hirsh J: Clot-bound thrombin is protected from inhibition by
heparin-antithrombin III but is susceptible to inactivation by
antithrombin III-independent inhibitors. J Clin Invest. 86:385–391.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Begonja AJ, Geiger J, Rukoyatkina N,
Rauchfuss S, Gambaryan S and Walter U: Thrombin stimulation of p38
MAP kinase in human platelets is mediated by ADP and thromboxaneA2
and inhibited by cGMP/cGMP-dependent protein kinase. Blood.
109:616–618. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Malaver E, Romaniuk MA, D’atri LP, Pozner
RG, Negrotto S, Benzadón R and Schattner M: NF-kappaB inhibitors
impair platelet activation responses. J Thromb Haemost.
7:1333–1343. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shankar H, Garcia A, Prabhakar J, Kim S
and Kunapull SP: P2Y12 receptor-mediated potentiation of
thrombin-induced thromboxane A2 generation in platelets occurs
through regulation of Erk1/2 activation. J Thromb Haemost.
4:638–647. 2006. View Article : Google Scholar
|
|
33
|
Liu J, Schuff-Werner P and Steiner M:
Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and
VEGF expression in prostate cancer cells. Biochem Biophys Res
Commun. 343:183–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang LH, Chen CH, Huang DY, Pai HC, Pan
SL and Teng CM: Thrombin induces expression of twist and cell
motility via the hypoxia-inducible factor-1α translational pathway
in colorectal cancer cells. J Cell Physiol. 226:1060–1068.
2011.PubMed/NCBI
|
|
35
|
Sil H, Sen T and Chatterjee A:
Fibronectin-integrin (alpha5beta1) modulates migration and invasion
of murine melanoma cell line B16F10 by involving MMP-9. Oncol Res.
19:335–348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu CT, Wu JR, Cheng CC, Wang S, Wang HT,
Lee MC, Wang LJ, Pan SM, Chang TY and Wu WS: Reactive oxygen
species-mediated PKC and integrin signaling promotes tumor
progression of human hepatoma HepG2. Clin Exp Metastasis.
28:851–863. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sood AK, Fletcher MS, Coffin JE, Yang M,
Seftor EA, Gruman LM, Gershenson DM and Hendrix MJC: Functional
role of matrix metalloproteinases in tumor cell plasticity. Am J
Obstet Gynecol. 190:899–909. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sharma N, Seftor RE, Seftor EA, Gruman LM,
Heidger PM Jr, Cohen MB, Lubaroff DM and Hendrix MJ: Prostatic
tumor cell plasticity involves cooperative interactions of distinct
phenotypic subpopulations: role in vasculogenic mimicry. Prostate.
50:189–201. 2002. View Article : Google Scholar
|
|
39
|
Leger AJ, Jacques SL, Badar J, Kaneider
NC, Derian CK, Andrade-Gordon P, Covic L and Kuliopulos A: Blocking
the protease-activated receptor 1–4 heterodimer in
platelet-mediated thrombosis. Circulation. 113:1244–1254. 2006.
|
